Many of my research efforts have addressed key questions of the molecular pharmacology of receptors and ion channels, particularly those GPCRs which bind peptide hormones and neuropeptides. More recent studies have focussed upon the development of cell penetrating peptides and bioportides. These investigations have necessarily required the development of expertise in a broad repertoire of skills within the related fields of biochemistry and molecular cell biology.
Peptide design and synthesis provides de novo materials for a variety of internal and external research projects. Current efforts are predominantly focused upon the development of bioactive cell penetrating peptides, alternatively named bioportides, for a variety of applications that include both Parkinson’s disease and reproductive endocrinology.
• Professor of Molecular Pharmacology, University of Wolverhampton, UK.
• Honorary Research Fellow, School of Biosciences, University of Birmingham, UK
• Director of PanTechnia PLC.
• Elected UK Council Representative of the European Peptide Society.
• Council Member of the Royal Society of Chemistry, Peptide and Protein Science Group.
• Head of Pharmacology, School of Pharmacy, Faculty of Science and Engineering.
• Elected member of the European Peptide Society, American Peptide Society, FASEB, European Neuropeptide Club and Institute of Nanotechnology.
• Member of the Michael J Fox Foundation for Parkinson’s Disease, LRRK2 Consortium, New York, USA.
• Scientific Advisor to Cambridge Research Biochemicals.
Chimeric constructs between glioma-homing peptide and cell-penetrating peptides, gHoPe2. Filed 07/06/2012; Reference 12171160.0 – 1216.
This is a co-invention with collaborators in the universities of Stockholm, Helsinki and Tartu. The patent describes the synthesis, properties and potential applications of a glioma-homing drug delivery system.
Invited Research Presentations